Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 23, Issue 27, 2005, Pages 6674-6681

  Butts, Charles ^a   Murray, Nevin ^b   Maksymiuk, Andrew ^b   Goss, Glenwood ^b   Marshall, Ernie ^b   Soulières, Denis ^b   Cormier, Yvon ^b   Ellis, Peter ^b   Price, Allan ^b   Sawhney, Ravinder ^b   Davis, Mary ^b   Mansi, Janine ^b   Smith, Colum ^b   Vergidis, Dimitrios ^b   Ellis, Paul ^b   MacNeil, Mary ^b   Palmer, Martin ^b  

^a CROSS CANCER INSTITUTE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLP 25; CANCER VACCINE; CYCLOPHOSPHAMIDE; LIPOSOME; UNCLASSIFIED DRUG; VACCINE;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HEALTH STATUS; HUMAN; IMMUNE RESPONSE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SUSTAINED RELEASE PREPARATION; T LYMPHOCYTE; AGED; COMPARATIVE STUDY; CONFIDENCE INTERVAL; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REFERENCE VALUE; RISK ASSESSMENT; SALVAGE THERAPY; SURVIVAL; TREATMENT OUTCOME;

AGED; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CONFIDENCE INTERVALS; FEMALE; HUMANS; LIPOSOMES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REFERENCE VALUES; RISK ASSESSMENT; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 27244449289     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.13.011     Document Type: Article

References (30)

1. National Cancer Institute of Canada: Canadian Cancer Statistics 2004. Toronto, Ontario, Canada, National Cancer Institute of Canada, 2004
2. American Cancer Society: Cancer Facts and Figures, 2004. Atlanta, GA, American Cancer Society, 2004
3. Cameron R, Fringer J, Taylor C, et al: Practice guidelines for non-small cell lung cancer. Cancer J Sci Am 2:S61, 1996
4. American Society of Clinical Oncology: Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 15:2996-3018, 1997
5. Breathnach OS, Freidlin B, Conley B, et al: Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results. J Clin Oncol 19:1734-1742, 2001
6. American Society of Clinical Oncology: Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer: Update 2003. J Clin Oncol 22:330-352, 2004
7. Socinski MA, Schell MJ, Peterman A, et al: Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20:1335-1343, 2002
8. Smith IE, O'Brien MER, Talbot DC, et al: Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six course of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19:1336-1343, 2001
9. Depierre A, Quoix E, Mercier M, et al: Maintenance chemotherapy in advanced non-small cell lung cancer (NSCLC): A randomized study of vinorelbine (V) versus observation (OB) in patients (Pts) responding to induction therapy (French Cooperative Oncology Group). Proc Am Soc Clin Oncol 20:309a, 2001 (abstr 1231)
10. Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 22:785-794, 2004
11. Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 22:777-784, 2004
12. Gatzemeier U, Pluzanska A, Szczesna A, et al: Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 23:617, 2004 (suppl 14S, abstr 7010)
13. Herbst RS, Prager D, Hermann R, et al: TRIBUTE: A phase III trial of erlotinib HCI (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 23:617, 2004 (suppl 14S, abstr 7011)
14. Gatzemeier U, Groth G, Butts C, et al: Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 15:19-27, 2004
15. Hege KM, Carbone DP: Lung cancer vaccines and gene therapy. Lung Cancer 41:S103-S113, 2003
16. Ho SB, Niehans GA, Lyftogt C, et al: Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 53:641-651, 1993
17. Zotter S, Hageman PC, Lossnitzer A, et al: Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 11:55-101, 1988
18. Guan HH, Budzynski W, Koganty R, et al: Liposomal formulations of synthetic MUC1 peptides: Effects of encapsulation versus surface display of peptides on immune responses. Bioconjug Chem 9:451-458, 1998
19. Palmer M, Parker J, Modi S, et al: Phase I study of BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB-IV non-small cell lung cancer. Clin Lung Cancer 3:49-57, 2001
20. Reddish MA, MacLean GD, Poppema S, et al: Pre-immunotherapy serum CA27.29 (MUC1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother 42:303-309, 1996
21. MacLean GD, Reddish MA, Koganty RR, et al: Antibodies against mucin-associated Sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol 19:59-68, 1996
22. MacLean GD, Miles DW, Rubens RD, et al: Enhancing the effect of theratope STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 19:309-316, 1996
23. Bass KK, Mastrangelo MJ: Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother 47:1-12, 1998
24. Machiels J-P, Reilly RT, Emens LA, et al: Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61:3689-3697, 2001
25. Cella DF, Bonomi AE, Lloyd SR, et al: Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12:199-220, 1995
26. Maione P, Rossi A, Airoma G, et al: The role of targeted therapy in non-small cell lung cancer. Crit Rev Oncol Hematol 51:29-44, 2004
27. Giaccone G, Debruyne C, Felip E, et al: Phase III study of BEC2/BCG vaccination in limited disease small cell lung cancer (LD-SCLC) patients, following response to chemotherapy and thoracic irradiation (EORTC 08971, the SILVA study). J Clin Oncol 22:XXX, 2004 (suppl 14S, abstr 7020)
28. Nemunaitis J, Sterman D, Jablons D, et al: Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 96:326-331, 2004
29. Liu M, Acres B, Balloul JM, et al: Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci U S A 101:14567-14571, 2004 (suppl 2)
30. + T-cell responses to MAGE-3 protein in lung cancer patients. J Immunol 172:3289-3296, 2004